Kentaro Tamaki（Department of Breast Surgery,Nahanishi clinic,Okinawa,Japan;Department of Pathology,Tohoku University Hospital,1-1 Seiryo-machi,Aoba-ku Sendai,Miyagi 980-8574,Japan ） Hironobu Sasano（Department of Pathology,Tohoku University Hospital,1-1 Seiryo-machi,Aoba-ku Sendai,Miyagi 980-8574,Japan ）
被引量：2
Kentaro Tamaki（Department of Breast Surgery,Nahanishi clinic,Okinawa,Japan;Department of Pathology,Tohoku University Hospital,1-1 Seiryo-machi,Aoba-ku Sendai,Miyagi 980-8574,Japan ） Hironobu Sasano（Department of Pathology,Tohoku University Hospital,1-1 Seiryo-machi,Aoba-ku Sendai,Miyagi 980-8574,Japan ）
1Goldhrirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009 [J]. Ann Oneol, 2009, 20(8) : 1319-1329.
2Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [ J ]. Ann Oncol. 2011, 22(8) : 1736-1747.
3Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors [J]. Nature, 2000, 406(6797) : 747-752.
4Sorlie T, Perou CM, Tibshirani R, et al. Gene expression pattern of breast carcinomas distinguish tumor subclasses with clinical implications [ J]. Proc Natl Acad Sci, 2001,98 (19) : 10 869-10 874.
5Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis [J]. Mod Pathol, 1998, 11(2) : 155-168.
6Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer [ J]. J Clin Oncol, 1999, 17 (5) : 1474-1481.
7Kurosumi M. Immunohistochemical assessment of hormone receptor status using a new scoring system (J-Score) in breast cancer [J]. Breast Cancer, 2007, 14(2) : 189-193.
8Hammond MEH, Hayes DF, Dowsett M, et al. American society of clinical oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[ J]. J Clin Oncol, 2010, 28(16): 2784-2795.
9Slamon DJ, Clark GM. Amplification of C-ERB-B2 and aggressive breast tumors [ J ]. Science, 1988, 240 (4860) : 1795-1798.
10De Potter CR. The neu oncogene: motv than a prognostic indicator.? [J]. Hum Pathol, 1994, 25(12) : 1264-1268.
